|
KMID : 0391319930030020231
|
|
Korean Journal of Biological Response Modifiers
1993 Volume.3 No. 2 p.231 ~ p.238
|
|
|
Effect of Therapeutic Administration of G-CSF in Neutropenic Patients Undergoing Chemotherapy for Cancer
|
|
최철원
남용진/신상원/김준석/김열홍
|
|
|
Abstract
|
|
|
Background:
@EN The administration of granulocyte colony-stimulating factor (G-CSF) after standard dose chemotherapy may be either prophylactic (i.e., given to prevent infectious complications) ro therapeutic (i.e., given to patients who have neutropenia),
and
the
beneficial effect of prophylactic administration of G-CSF was proved in many studies. We undertook study to investigate the therapeutic effect of G-CSF in patients became neutropenic after anticancer chemotherapy.
@ES Method:
@EN The total number of patients were twenty; six with lung cancer, five with bone tumor, four with stomach cancer, three wit head and neck cancer, and two with other malignancies. The patients were received anticancer chemotherapy and begun to
be
administered G-CSF 125㎍/day subcutaneously when they became neutropenic (total neutrophil count less than 1,000/㎣), and until neutrophil count increased upto 2,000/㎣.
@ES Results:
@EN The mean interval from the first day of chemotherapy to the neutropenia was 14.8±3.0days and mean nadir neutrophil count was 366.2±242.2/㎣. The neutrophil count increased above 2,000/㎣ in 2nd day of rhG-CSF administration in 65% of
patients, 4th
day 85%, 6th day 95%, and 8th day 100%. The mean duration of rhG-CSF administration was 4.6±3.2days and the mean duration of neutropenia was 3.1±1.2 days. The incidence and mean duration of neutropenic fever was 35%(7/20) and 1.2±1.0 days,
respectively. And no serious side effect was observed.
@ES Conclusion:
@EN rhG-CSF effectively increases neutrophil count in neutropenic patients undergoing chemotherapy for cancer without serious side effect but clinical benefit must be weighed in the future.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|